ABPA

USAID-funded TRANSFORM Project Secures Additional Private Sector Support for Antimicrobial Use Stewardship Principles, Now Includes Over 30% of Global Broiler Production

Retrieved on: 
Tuesday, November 14, 2023
Pharmaceutical, Environmental Health, Animal Welfare, Agriculture, Infectious Diseases, Food, Beverage, Natural Resources, Environment, Retail, Veterinary, Health, Public Policy, Government, Global health, Organization, Hope, USAID, PFI, Heifer International, Infection, Zoonosis, Global Health, Risk, One Health, Cargill, Multimedia, Private sector, VIPA, Ecosystem, Animal, Global Health Security Agenda, AMR, ABPA, IPC, Human, Diagnosis, TBA, Poultry, Poultry farming

As part of TRANSFORM, the International Poultry Council (IPC) is driving global change within animal agriculture by uniting poultry industry associations and private sector organizations to support antimicrobial use stewardship principles that guide actions to avoid the need to use, but when needed, ensure proper use of antimicrobials.

Key Points: 
  • As part of TRANSFORM, the International Poultry Council (IPC) is driving global change within animal agriculture by uniting poultry industry associations and private sector organizations to support antimicrobial use stewardship principles that guide actions to avoid the need to use, but when needed, ensure proper use of antimicrobials.
  • By adopting or endorsing the principles, organizations commit to encouraging or taking action that centers around four key points.
  • Second, organizations agree to adopt farm management practices that improve animal health and would reduce the need for antimicrobial use.
  • “By advancing science-based antimicrobial use stewardship principles, we are able to create an ecosystem where animal health improves, the need for antibiotic use decreases, and animal production increases.

Pulmatrix Supports World Asthma Day 2023

Retrieved on: 
Tuesday, May 2, 2023
Exercise, ABPA, Asthma, Wheeze, Clinical trial, Pollen, Cough, Allergic bronchopulmonary aspergillosis, Lung, Pulmonary fibrosis, Patient, Smoke, Itraconazole, Dust, Cystic fibrosis, Aspergillus fumigatus, United Kingdom, Conditional sentence, Pharmaceutical industry

LEXINGTON, Mass., May 2, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology, today announced its support for World Asthma Day.

Key Points: 
  • LEXINGTON, Mass., May 2, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology, today announced its support for World Asthma Day.
  • Margaret Wasilewski, M.D., Chief Medical Officer of Pulmatrix, commented, "World Asthma Day is an important time of recognition for the 250 million patients worldwide with this chronic disease.
  • We are proud to support this important day and grateful for the potential opportunity to positively impact the asthma patient community."
  • For more about Pulmatrix inhaled product candidates, including PUR1900 (an inhaled form of itraconazole being developed for allergic broncho-pulmonary aspergillosis in patients with asthma), please visit: https://www.pulmatrix.com/pipeline.html .

New Expert Analysis Finds that Without Legislative Action, Vehicle Owners will Pay Significantly More for Repairs

Retrieved on: 
Tuesday, September 20, 2022
Diamond, Car, Adoption, Safety, Motor Vehicle Owners' Right to Repair Act, Policy, Sale, Problematic social media use, Republican, AutoZone, Face, Industry, DePaul University College of Law, University of Michigan Law School, Allstate, National Highway Traffic Safety Administration, Certified Automotive Parts Association, CAPA, LKQ Corporation, Solution, REPAIR, ABPA, White House, Competition regulator, Research, SMART, Congress, Multimedia, University, CarParts.com, Patent, View, NHTSA, Consumer electronics, Car dealership, Farmer

WASHINGTON, Sept. 20, 2022 /PRNewswire/ -- The CAR Coalition, a growing group of independent automotive parts, management and repair companies, associations, and insurers committed to preserving consumer choice and affordable vehicle repair, today released two official research papers focused on the impact of right to repair legislation in the auto industry. The two papers, which are focused on the REPAIR Act (H.R. 6570), authored by Aaron Perzanowski of University of Michigan Law School, and the SMART Act (H.R. 3664), authored by Joshua Sarnoff of DePaul University College of Law, argue that in the face of rising costs and restrictions to auto repairs, consumers will face even higher costs without legislative action.

Key Points: 
  • 6570 ), authored by Aaron Perzanowski of University of Michigan Law School, and the SMART Act ( H.R.
  • Key excerpts from Professor Aaron Perzanowski's paper focused on the REPAIR Act include:
    "Compared to independent repair shops, dealerships charge consumers 36% more for repairs."
  • "By denying consumers and their preferred independent repair providers access to this crucial information, carmakers and dealers can reduce competition and increase the cost of vehicle repairs."
  • "The REPAIR Act offers a sensible, forward looking, nationwide solution that protects the rights of vehicle owners and promotes a robustly competitive repair industry."

TFF Pharmaceuticals Announces Final Data from Phase 1b Study of Inhaled Voriconazole Powder in Asthma Patients

Retrieved on: 
Tuesday, December 21, 2021
GLOBE, FDA, Infection, Allergic bronchopulmonary aspergillosis, Absorption, CEO, Annual report, Voriconazole, World Science Day for Peace and Development, Inclusion, Diagnosis, Toxic leukoencephalopathy, NASDAQ, Safety, Science, Inhalation, TFF, Pharmacokinetics, Risk, Infectious Diseases Society of America, Patient, COPD, Asthma, Invasive, Company, Bronchoconstriction, Lung, Cystic fibrosis, Population, Chronic obstructive pulmonary disease, ABPA, Solubility, Bronchospasm, IPA, NCT, Pharmaceutical industry, Aspergillosis

AUSTIN, Texas, Dec. 21, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the full readout of safety and pharmacokinetic (PK) data from its Phase 1b study (NCT #04576325) of Inhaled Voriconazole Powder (TFF VORI) in asthma patients.

Key Points: 
  • TFF VORI is a next-generation, direct-to-lung, inhaled dry powder formulation of voriconazole for the treatment and prevention of Invasive Pulmonary Aspergillosis (IPA).
  • TFF Pharmaceuticals proprietary Thin Film Freezing technology platform allows the reformulation of voriconazole into a dry powder with properties ideally suited for inhalation.
  • The data reported from the Phase 1b study are consistent with the initial data reported in November suggesting that TFF VORI is well tolerated in asthma patients and could therefore provide a differentiating benefit to a broad population of patients with IPA.
  • TFF Pharmaceuticalshas two lead drug candidates: Inhaled Voriconazole Powder and Inhaled Tacrolimus Powder.

TFF Pharmaceuticals Announces Completion of Dosing of Phase 1b Study for Voriconazole Inhalation Powder in Mild to Moderate Asthma Patients

Retrieved on: 
Monday, November 8, 2021
Population, Chronic obstructive pulmonary disease, Bronchospasm, COVID-19, Amikacin, Infection, Voriconazole, Absorption, Bronchoconstriction, Lung, Asthma, Risk, Safety, Allergic bronchopulmonary aspergillosis, Diagnosis, Toxic leukoencephalopathy, BID, ABPA, GLOBE, Patient, FDA, Invasive, IDSA, Phase II, NASDAQ, CEO, VIP, Solubility, IPA, NCT, Pharmacokinetics, Cystic fibrosis, COPD, Â, Severe acute respiratory syndrome coronavirus 2, Niclosamide, Tacrolimus, Annual report, TFF, Company, Inhalation, Pharmaceutical industry

AUSTIN, Texas, Nov. 08, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the completion of dosing in the Phase 1b clinical trial of Voriconazole Inhalation Powder (TFF VORI), a next-generation, direct-to-lung, inhaled dry powder version of voriconazole for the treatment and prevention of Invasive Pulmonary Aspergillosis (IPA) (NCT #04576325). This study assessed the safety and tolerability of patients with mild to moderate asthma, a population at high risk of developing IPA, in two cohorts of eight patients. Initial data from the study suggests that TFF VORI is well tolerated in asthma patients, supporting the Company’s progress to Phase 2 study in IPA patients.

Key Points: 
  • This study assessed the safety and tolerability of patients with mild to moderate asthma, a population at high risk of developing IPA, in two cohorts of eight patients.
  • Initial data from the study suggests that TFF VORI is well tolerated in asthma patients, supporting the Companys progress to Phase 2 study in IPA patients.
  • By assessing asthma patients in this Phase 1b reactive airway, we hope to demonstrate that our Voriconazole Inhalation Powder would allow for treatment of patients with IPA that have hyperreactive airway disease comorbidities.
  • This Phase 1b reactive airway study is a randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability, pharmacokinetics, and induction of bronchospasm of Voriconazole Inhalation Powder (VIP) in 16 patients with mild to moderate asthma patients.

Allergic Bronchopulmonary Aspergillosis | 2019 Pipeline Insight Report Featuring Key Players: Pulmatrix, Cipla and Pulmocide - ResearchAndMarkets.com

Retrieved on: 
Monday, October 21, 2019
Health, Pharmaceutical, ABPA, Allergic bronchopulmonary aspergillosis, Aspergillosis, Veterinary medicine, Medicine

The "Allergic Bronchopulmonary Aspergillosis Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Allergic Bronchopulmonary Aspergillosis Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • A detailed picture of the Allergic Bronchopulmonary Aspergillosis pipeline landscape is provided which includes the disease overview and Allergic Bronchopulmonary Aspergillosis treatment guidelines.
  • The assessment part of the report embraces, in depth Allergic Bronchopulmonary Aspergillosis commercial assessment and clinical assessment of the pipeline products under development.
  • Allergic Bronchopulmonary Aspergillosis (ABPA) pipeline report covers 3+ companies.